Open an account

Smith & Nephew

SNN · LONDON

$30.83−$0.05 (−0.16%)TodayMarket closed ·
Prev close $30.88

About SNN

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire and currently employs 16,988 full-time employees. The firm is focused on the repair, regeneration, and replacement of soft and hard tissue. The firm's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The firm also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system.

Employees
16,988
Headquarters
Watford, Hertfordshire
Listed
Aug 13, 1951
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
smith-nephew.com

SNN key statistics

Market cap
9.49B
Price-earnings ratio
0.00
Dividend yield
2.62%
Average volume
1.21M
Volume
1.34M
Open price
$31.12
High today
$31.21
Low today
$30.83
52 Week high
$37.08
52 Week low
$26.12

Smith & Nephew (SNN) at a glance

Smith & Nephew (SNN) last traded at $30.83, with a market cap of 9.49B, a price-to-earnings ratio of 0.00 and a dividend yield of 2.62%.

Today the stock has traded between $30.83 and $31.21. The current price is 0.0% above the day's low and 1.2% below its high.

Volume so far is 1.34M shares, in line with the average of 1.21M shares a day.

Over the past year Smith & Nephew has ranged from $26.12 to $37.08, and now sits 43% of the way up that range.

Smith & Nephew met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q4 FY14 it reported $0.26 per share against an estimate of $0.2586.

SNN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 1.8% on average.

  1. Q1 FY13: reported $0.184 per share against an estimate of $0.1881
  2. Q2 FY13: reported $0.179 per share against an estimate of $0.1854
  3. Q3 FY13: reported $0.17 per share against an estimate of $0.174
  4. Q4 FY13: reported $0.232 per share against an estimate of $0.2299
  5. Q1 FY14: reported $0.177 per share against an estimate of $0.1862
  6. Q2 FY14: reported $0.204 per share against an estimate of $0.1962
  7. Q3 FY14: reported $0.195 per share against an estimate of $0.1974
  8. Q4 FY14: reported $0.26 per share against an estimate of $0.2586

SNN news

  • Press releaseACCESS Newswire

    Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

  • Press releaseACCESS Newswire

    Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds

  • Press releaseACCESS Newswire

    Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m

  • Avi Kapoor

    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

  • Press releasePRNewswire

    Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

  • Press releaseGlobe Newswire

    A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

  • Press releaseGlobe Newswire

    A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching

  • Avi Kapoor

    Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good'

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.